Literature DB >> 16360555

Imputing missing standard deviations in meta-analyses can provide accurate results.

Toshi A Furukawa1, Corrado Barbui, Andrea Cipriani, Paolo Brambilla, Norio Watanabe.   

Abstract

BACKGROUND AND OBJECTIVES: Many reports of randomized controlled trials (RCTs) fail to provide standard deviations (SDs) of their continuous outcome measures. Some meta-analysts substitute them by those reported in other studies, either from another meta-analysis or from other studies in the same meta-analysis. But the validity of such practices has never been empirically examined.
METHODS: We compared the actual standardized mean difference (SMD) of individual RCTs and the meta-analytically pooled SMD of all RCTs against those based on the above-mentioned two imputation methods in two meta-analyses of antidepressants.
RESULTS: Two meta-analyses included 39 RCTs of fluoxetine (n = 3,681) and 25 RCTs of amitriptyline (n = 1,832), which had actually reported means and SDs of the Hamilton Rating Scale for Depression. According to either of the two proposed imputation methods, the agreement between actual SMDs and imputed SMDs for individual RCTs was very good with ANOVA intraclass correlation coefficients between 0.61 and 0.97. The agreement between the actual pooled SMD and the imputed one was even better, with minimal differences in both their point estimates and 95% confidence intervals.
CONCLUSION: For a systematic review where some of the identified trials do not report SDs, it appears safe to borrow SDs from other studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16360555     DOI: 10.1016/j.jclinepi.2005.06.006

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  392 in total

Review 1.  Zotepine versus other atypical antipsychotics for schizophrenia.

Authors:  Selvizhi Subramanian; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Werner Kissling; Stefan Leucht; Katja Komossa
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

Review 2.  Mirtazapine versus other antidepressive agents for depression.

Authors:  Norio Watanabe; Ichiro M Omori; Atsuo Nakagawa; Andrea Cipriani; Corrado Barbui; Rachel Churchill; Toshi A Furukawa
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

Review 3.  Cognitive behavioural therapy (brief versus standard duration) for schizophrenia.

Authors:  Farooq Naeem; Saeed Farooq; David Kingdon
Journal:  Cochrane Database Syst Rev       Date:  2015-10-21

Review 4.  Omega-3 fatty acids for depression in adults.

Authors:  Katherine M Appleton; Hannah M Sallis; Rachel Perry; Andrew R Ness; Rachel Churchill
Journal:  Cochrane Database Syst Rev       Date:  2015-11-05

Review 5.  Supportive therapy for schizophrenia.

Authors:  Lucy A Buckley; Nicola Maayan; Karla Soares-Weiser; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2015-04-14

6.  Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis.

Authors:  M Yates; Y K Loke; R A Watts; A J MacGregor
Journal:  Clin Rheumatol       Date:  2013-09-12       Impact factor: 2.980

Review 7.  Crisis intervention for people with severe mental illnesses.

Authors:  Suzanne Murphy; Claire B Irving; Clive E Adams; Ron Driver
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 8.  Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.

Authors:  Ehete Bahiru; Angharad N de Cates; Matthew Rb Farr; Morag C Jarvis; Mohan Palla; Karen Rees; Shah Ebrahim; Mark D Huffman
Journal:  Cochrane Database Syst Rev       Date:  2017-03-06

Review 9.  Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis.

Authors:  Iñaki Imaz; Carmen Martínez-Cervell; Elvira Elena García-Alvarez; Juan Manuel Sendra-Gutiérrez; Jesús González-Enríquez
Journal:  Obes Surg       Date:  2008-05-06       Impact factor: 4.129

Review 10.  Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.

Authors:  I Imaz; P Zegarra; J González-Enríquez; B Rubio; R Alcazar; J M Amate
Journal:  Osteoporos Int       Date:  2009-12-05       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.